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STUDY PROTOCOL Open Access
Danish study of Non-Invasive testing in
Coronary Artery Disease (Dan-NICAD): study
protocol for a randomised controlled trial
Louise Nissen1*, Simon Winther1,2, Christin Isaksen4, June Anita Ejlersen3, Lau Brix4, Grazina Urbonaviciene5,
Lars Frost5, Lene Helleskov Madsen1, Lars Lyhne Knudsen1, Samuel Emil Schmidt6, Niels Ramsing Holm2,
Michael Maeng2, Mette Nyegaard7, Hans Erik Bøtker2 and Morten Bøttcher1
Abstract
Background: Coronary computed tomography angiography (CCTA) is an established method for ruling out
coronary artery disease (CAD). Most patients referred for CCTA do not have CAD and only approximately 20–30 % of
patients are subsequently referred to further testing by invasive coronary angiography (ICA) or non-invasive perfusion
evaluation due to suspected obstructive CAD. In cases with severe calcifications, a discrepancy between CCTA and ICA
often occurs, leading to the well-described, low-diagnostic specificity of CCTA. As ICA is cost consuming and involves a
risk of complications, an optimized algorithm would be valuable and could decrease the number of ICAs that do not
lead to revascularization.
The primary objective of the Dan-NICAD study is to determine the diagnostic accuracy of cardiac magnetic resonance
imaging (CMRI) and myocardial perfusion scintigraphy (MPS) as secondary tests after a primary CCTA where CAD could
not be ruled out. The secondary objective includes an evaluation of the diagnostic precision of an acoustic technology
that analyses the sound of coronary blood flow. It may potentially provide better stratification prior to CCTA
than clinical risk stratification scores alone.
Methods/design: Dan-NICAD is a multi-centre, randomised, cross-sectional trial, which will include approximately
2,000 patients without known CAD, who were referred to CCTA due to a history of symptoms suggestive of CAD and a
low-risk to intermediate-risk profile, as evaluated by a cardiologist. Patient interview, sound recordings, and
blood samples are obtained in connection with the CCTA. All patients with suspected obstructive CAD by
CCTA are randomised to either stress CMRI or stress MPS, followed by ICA with fractional flow reserve (FFR)
measurements. Obstructive CAD is defined as an FFR below 0.80 or as high-grade stenosis (>90 % diameter
stenosis) by visual assessment.
Diagnostic performance is evaluated as sensitivity, specificity, predictive values, likelihood ratios, and C statistics.
Enrolment commenced in September 2014 and is expected to be complete in May 2016.
Discussion: Dan-NICAD is designed to assess whether a secondary perfusion examination after CCTA could safely
reduce the number of ICAs where revascularization is not required. The results are expected to add knowledge about
the optimal algorithm for diagnosing CAD.
Trial registration: Clinicaltrials.gov identifier, NCT02264717. Registered on 26 September 2014.
Keywords: Coronary artery disease, Coronary computed tomography angiography, Myocardial perfusion scintigraphy,
Cardiac magnetic resonance imaging, Coronary angiography, Fractional flow reserve
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Background
An increasing number of patients are referred for evalu-
ation of coronary artery disease (CAD) based on atypical
symptoms. No unequivocal diagnostic strategy has been
established for diagnosing CAD in patients presenting
with symptoms suggestive of stable angina pectoris, and
for that reason, clinical practice varies around the world.
The gold standard for detecting hemodynamic ob-
structive CAD is invasive coronary angiography (ICA)
with fractional flow reserve (FFR) measurement [1–3].
However, ICA is costly and involves a small risk of com-
plications and death [4]. Coronary computed tomog-
raphy angiography (CCTA) has become an established
procedure to examine patients with a low to intermedi-
ate risk of CAD [5–11]. Due to high negative predictive
value, obstructive CAD can be excluded by CCTA in ap-
proximately 70–80 % of these patients [11], depending
on the risk of the referred population. However, CCTA
has consistently proven to have a low positive predictive
value, often resulting in an overestimation of the severity
of CAD [12], especially in patients with moderate to se-
vere coronary calcification. Consequently, the introduc-
tion of CCTA has not led to a substantial decrease in
the number of annually performed ICAs or increased
the frequency of revascularisation procedures following
ICA [13]. The above-mentioned issues raise the question
of whether it is possible (1) to make a more precise risk
stratification and consequently better selection of pa-
tients prior to CCTA and (2) to reduce the number of
patients referred for unnecessary ICAs after CCTA.
European guidelines recommend conducting a myo-
cardium perfusion examination after CCTA to reduce
the number of ICAs when no revascularization is per-
formed [14], although disagreement still exists regarding
which perfusion examination to use.
Cardiac magnetic resonance imaging (CMRI) offers
many advantages such as no radiation exposure and
high image resolution [15–20]. A lack of scanner cap-
acity and expertise are often mentioned as limitations.
Myocardial perfusion scintigraphy (MPS) is an estab-
lished perfusion test; however, disadvantages such as
radiation and low sensitivity are reported as well as a
balanced reduction in blood flow to the myocardium
in three-vessel disease [21–24]. Many studies asses-
sing the diagnostic accuracy of CMRI and MPS have
used ICA diameter stenosis as a reference standard
[16, 18[20, 22], which has been shown to be inaccur-
ate in assessing the functional significance of a coronary
stenosis compared to ICA-FFR [3].
A meta-analysis on MPS found an average sensitivity
of 84 % for women and 89 % for men and a specificity of
78 % for women and 71 % for men using invasive coron-
ary angiography– quantitative coronary angiography
(ICA-QCA) as a reference standard [25]. For CMRI, a
meta-analysis of studies performed with ICA-FFR as the
reference found an average sensitivity of 90 % and a spe-
cificity of 87 % [17].
The CADScor System (Acarix A/S, Denmark) is a
newly developed technology, which automatically ana-
lyses sounds from the heart and extracts multiple acous-
tic features related to turbulent blood flow, which
emerges in a coronary segment with stenosis, and other
heart sounds characteristic to CAD [26–29]. Based on
these characteristics, the system calculates a score. This
score can potentially be used for risk stratification prior
to CCTA and in diagnosing CAD [29].
The first objective of the present study is to determine
the precision of MPS and CMRI as secondary examina-
tions after CCTA when significant stenosis cannot be
excluded.
Our second objective is to examine the diagnostic pre-
cision of the CAD score in patients with a low to inter-
mediate risk of CAD and who have been referred to a
primary examination by CCTA.
Methods/design
Study design
Dan-NICAD is an investigator-initiated, multi-centre,
randomised, cohort trial examining patients without
known CAD, who have been referred to CCTA due to a
history of symptoms suggestive of CAD. Study subjects
are being recruited at two regional hospitals (Depart-
ment of Cardiology, Regional Hospitals of Herning and
Silkeborg, Denmark). Approximately 2,000 patients with
low to intermediate risk of CAD will be included and
possibly supplied if needed until a minimum of 300 pa-
tients have been randomised and completed perfusion
imaging. It is expected that 1,000 patients will be en-
rolled at each site, as the two centres have similar annual
activity in terms of performed CCTAs. Patients with a
normal CCTA will not undergo further evaluation,
whereas patients with suspected obstructive CAD on
CCTA are being randomised. Randomisation is 1:1 for
either CMRI or MPS, with subsequent ICA with FFR
analysis in both arms. A patient flowchart is included in
Fig. 1. All perfusion examinations will be conducted at
the two regional hospitals, and the ICA with FFR will be
conducted at the Aarhus University Hospital, Aarhus,
Denmark. The cohort will be followed for clinical events
for 10 years.
Study population
The cohort consists of patients referred to CCTA with
low or intermediate pre-test probability for CAD. The
pre-test probability is based on a clinical assessment in
an outpatient cardiology setting. Inclusion and exclusion
criteria are listed in Table 1. In all enrolled patients, an
acoustic examination with the CADScor® system is
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performed, an interview is conducted, and a blood sam-
ple is obtained and stored in a biobank.
Blood samples
Four blood samples will be collected from all patients
before X-ray contrast medium is administered for the
CCTA. These samples will be centrifuged, and for each
patient, three 1-mL vials of serum, three 1-mL vials of
ethylenediaminetetraacetic acid (EDTA) plasma, and
three 1 mL vials of heparin plasma are being collected
with the purpose of creating a biobank. In addition, the
buffy coat layer from both the EDTA-buffered blood and
the heparin-buffered blood are being collected and
stored for the purpose of DNA and RNA isolation. All
samples are being stored in a -80 °C freezer. The pur-
pose of the biobank is to perform genetic analysis related
to risk factors and identify new biomarkers associated
with the development of arteriosclerosis. The details of
these analyses are beyond the scope of this paper.
Fig. 1 Danish study of Non-Invasive testing in Coronary Artery Disease (Dan-NICAD) patient flowchart. CAD, coronary artery disease; CCTA,
coronary computed tomography angiography; CMRI, cardiac magnetic resonance imaging; MPS, myocardial perfusion scintigraphy; ICA-FFR, invasive
coronary angiography-fractional flow reserve
Table 1 Study enrolment criteria
Criteria for inclusion
- Patients with low intermediate pre-test risk of CAD, with an indication
for CCTA
- Qualified patients who have signed a written informed consent form
Criteria for exclusion
- Age below 40
- Pregnant women, including women who are potentially pregnant
or lactating
- Contra-indication for adenosine (severe asthma, advanced AV block,
or critical aorta stenosis)
- Reduced kidney function, with an estimated glomerular filtration
rate (eGFR) < 40 mL/min.
- Contra-indications for MRI
- Allergy to X-ray contrast medium
- Previous PCI, CABG, or POBA
CAD coronary artery disease, CCTA coronary computed tomography
angiography, MRI, magnetic resonance imaging, PCI percutaneous coronary
intervention, CABG: coronary artery bypass grafting, POBA: plain old
balloon angioplasty
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CAD score
The acoustic heart score, which is the CAD score, is being
measured in connection with the CCTA examination.
Heart sound recordings are obtained with the micro-
phone from the CADScor system (Acarix A/S,
Denmark) mounted at the 4th intercostal space just left
to sternum using a dedicated patch. The patient has to
lie down for 3 min during the recordings and will be
asked to hold his/her breath four times for a duration of
7.5 s. As the equipment is sensitive to sounds coming
from the outside, tests are conducted in an undisturbed
room. Immediately afterward, the recording the equip-
ment will automatically calculate a CAD score. The
CAD score is estimated from a fully automated algo-
rithm, which extracts multiple acoustic features from the
diastolic heart sounds related to potential turbulence
murmurs and other heart sounds characteristics related
to CAD [26–29].
The CADScor system analyses the quality of the heart
sound; in cases of poor recording quality e.g. a high level
of ambient noise, the CADScor device will request a
new recording. In these cases, a second attempt is being
made to estimate the CAD score.
Coronary computed tomography angiography (CCTA)
Patient preparation
Prior to CCTA, patients are asked to abstain from cof-
fee, tea, and tobacco on the morning of the examination.
Ahead of scanning, most patients will be asked to take
50–100 mg of metoprolol or 7.5 mg of ibravadin in
order to obtain an optimal heart frequency below 65
beats per minute (BPM). Before imaging, patients with a
heart rate higher than 65 BPM will be administered
Seloken® (metoprolol tartrate 2.5–20 mg intravenous) if
there are no contraindications. Prior to the CCTA, all
patients receive 0.8 mg of sublingual nitroglycerin.
Imaging protocol
Scans are performed on a 320 multi-slice volume CT
scanner (Aquillion One, Toshiba Medical Systems, Japan)
using prospective electrocardiogram (ECG) gating.
After anteroposterior and lateral scanograms, a non-
enhanced scan will be performed using prospective ECG
triggering over a single heartbeat with a gantry rotation
and x-ray exposure time of 0.35 s, 0.5-mm slice collima-
tion, tube voltage of 120 kV, and the tube current auto-
matically adjusted with a noise index 80 standard
deviation (SD). The start and end positions are deter-
mined using the non-enhanced scan. To minimize radi-
ation exposure, the range is reduced as much as
possible. In most cases, z-axis coverage is 140 mm but
may range from 120 to 160 mm, depending on the
length of the heart. The CCTA protocol is performed
using a peak tube voltage of 100 kV, except for obese
patients where 120 kV is required, a gantry rotation time
of 0.35 s, and prospective ECG triggering. 50–80 mL non-
ionic contrast agent (Optiray 350 mg/mL, Mallinckrodt,
Ireland) is administrated according to patient weight.
Real-time bolus tracking is performed in the descending
aorta and begins 5 s after the start of the contrast injec-
tion. Once a target threshold of 180 Hounsfield units
(HU) is reached in the descending aorta, the CCTA will
be initiated during the pursuing breath hold.
Data are typically reconstructed at 65–75 % of the RR
interval, with supplemental reconstructions when needed.
A built-in PhaseExact (Toshiba Medical Systems, Japan)
transfers the best phase at slice thickness 0.5 mm to a
workstation (Vitrea Advanced Workstation, Vital Images,
Minnetonka, MN, USA).
Imaging analysis
An experienced cardiologist performs the analyses. An
Agatston calcium score is calculated using dedicated
software (Vitrea Advanced Workstation, Vital Images,
Minnetonka, MN, USA). Luminal diameter stenosis is
evaluated in each segment of the coronary tree using the
18-segment model of the Society of Cardiovascular
Computed Tomography [9]. Coronary lesions are quan-
tified by visual assessment, and severity is classified as
follows: no stenosis—0 % diameter reduction (≈ 0 % area
reduction); mild stenosis—1 to 29 % diameter reduction
(≈ 1 to 50 % area reduction); moderate stenosis—30 to
49 % diameter reduction (≈ 50 to 69 % area reduction);
and severe stenosis—50 to 100 % diameter reduction
(≈ 70 to 100 % area reduction). Severe stenosis and
non-evaluable segments with a diameter greater than
2 mm are defined as having obstructive CAD. CCTA
is defined as abnormal if obstructive CAD cannot be
ruled out in all coronary segments.
Myocardial perfusion scintigraphy (MPS)
Preparation
The patients are advised to abstain from caffeine (coffee,
tea, chocolate, and caffeinated medications) 24 h prior
to the examination. If possible, patients treated with
betablockers are asked to discontinue the treatment 48 h
prior to the stress test.
MPS protocol
The preferred stress test is a standard symptom-limited
exercise test on a bicycle (25 watt/2 min). If the patients
are unable to perform an exercise test or if discontinu-
ation of betablocker is contraindicated, a standard ad-
enosine stress test (6-min infusion of 140 μg/kg/min) is
performed. If adenosine is contraindicated (allergic
asthma or severe COLD defined as a FEV1 < 50 % of ex-
pected), patients will be stressed with dobutamine.
Tc99m-Sestamibi (10 MBq per kilogram of body weight)
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is injected at peak exercise or after 3 min of the adenosine
infusion, when the target heart rate (= (220 - age) * 0.85)
has been reached during the dobutamine infusion. Inde-
pendent of the stress modality, the heart rate, blood pres-
sure, and ECG are monitored throughout the test.
If the stress images are completely normal, no add-
itional rest study will be performed. If the stress images
reveal any suspicion of a perfusion or motion abnormal-
ity, a standard rest test (½ h of supine rest followed by
injection of 10 MBq Tc99m-Sestamibi per kilogram of
body weight) is conducted within 2 weeks.
MPS image acquisition
MPS is obtained in the supine position using a dedicated
gamma camera (Cardio MD, Phillips Healthcare, Best, Hol-
land) equipped with LEHR collimators and Vantage TM
Gadolinium-153 line sources. A step-and-shoot acquisition
in 64 projections, 20 s per emission projection, using a
180-degree RAO-LPO orbit and gating in eight frames, is
applied. The transmission and emission images are ob-
tained simultaneously. The duration of the transmission
scan determines the scan acquisition time based on the
Gd-153 source strength; i.e. 20 s per frame for new attenu-
ation correction-sources, increasing to 25 s per frame for
older sources (to ensure enough counts in AC image). The
energy window is set at 140 keV ± 10 % for the acquisition
of the emission images and at 100 keV ± 10 % for the ac-
quisition of the transmission images. An additional 118
keV ± 6 % photopeak window is used to compensate for
downscatter of Tc-99 m into the Gd-153 energy window.
After the stress acquisition, a nuclear technician re-
constructs the images (see details below), and a nuclear
medical physician decides if the patient should undergo
a rest test. The raw projection data from the stress and
the possible rest acquisitions are stored digitally.
The stress images are obtained within 1 hour after the
Tc injection if stress is performed with exercise or
adenosine-low exercise and within 3 h after supine ad-
enosine stress or dobutamine stress. The rest images are
acquired within 3 h after the injection.
Image reconstruction
After obtaining images, the raw image files will be de-
identified and processed by an experienced nuclear med-
ical physician using dedicated customized software [30]
Cedar Sinai AutoSPECT 3.5 in Phillips Intellispace
Portal v6.0.3.12200. An iterative maximum likelihood
estimation method algorithm (12 iterations) starting
out with a filtered back projection and using a But-
terworth analytic filter with a cut off of 0.5 and order
of 5.0 will be applied. Motion correction is added if
the successive projections move more than 1 pixel in
the y axis. Transmission data will be reconstructed
similarly except for the use of a cut off of 0.6 and an order
of 1.0. After the reconstruction, the left ventricle will be
reoriented in short, vertical, and horizontal long axes, and
these images will be saved for analysis.
Image analysis
Image analysis will be conducted in Cedar Sinai Auto-
Quant software in Phillips Intellispace Portal v6.0.3.12200
in an independent core lab by the same nuclear physician,
who is blinded to additional patient information and re-
sults. The quality of the stress and rest images will be eval-
uated semi-quantitatively on a visual scale from 1 to 3.
Scores defined as 1 represent a good image quality with no
artifacts; scores defined as 2 indicate moderate image qual-
ity, acceptable for clinical or research diagnosis; and scores
defined as 3 are consistent with poor image quality, and
diagnosing is impossible due to severe artifacts. The MPS
images are assessed using a 17-segment model. For each
segment, perfusion defects are scored automatically by the
software and adjusted visually on a five-point scoring sys-
tem (0 is normal, and 4 is the absence of tracer uptake).
The scores from the stress and rest images are summed,
and a summed stress score (SSS), summed rest score
(SRS), and summed difference score (SDS) will be pro-
duced. The images will also be evaluated qualitatively with
a binary outcome (normal/abnormal). An abnormal MPS
scan is defined as (1) an SDS ≥ 43? involving ≥ 2 contiguous
segments corresponding to approximately 10 % (reversible
ischemia); (2) an SRS ≥ 43? involving ≥ 2 contiguous seg-
ments (irreversible ischemia); (3) a combination of revers-
ible and irreversible ischemia involving ≥ 2 contiguous
segments (mixed ischemia). Poor image quality (score 3,
non-diagnostic) is considered abnormal (Fig. 2).
A hybrid imaging analysis, combined with information
from the CCTA and MPS, blinded from the result of the
ICA, is performed after the initial analysis.
Cardiac magnetic resonance imaging (CMRI)
Patient preparation and imaging hardware
Patients are advised to abstain from eating at least 2 h be-
fore scanning to avoid adverse side effects of the adeno-
sine, which include nausea and vomiting. Patients are also
advised to abstain from caffeine 24 h prior to the examin-
ation. The CMRI scans will be conducted using two iden-
tical 1.5 Tesla systems (Siemens MAGNETOM Avanto,
Software release VB17A, Siemens Healthcare GmbH,
Germany) using a dedicated 32-channel cardiac-receiver
coil. Blood pressure, distal oxygen saturation, and a vector
ECG will be monitored continuously during the examina-
tions using a MedRad® Veris® monitoring system (Bayer
Healthcare LCC, Berkeley, CA, USA).
All sequences are ECG gated, whereas motion artifacts
are minimized by breath-holding and navigator gating.
The total scan time is approximately 50 min, which in-
cludes patient preparation, scanner set-up, and imaging.
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A series of CMRI scans are included to enable the as-
sessment of information on cardiac morphology, func-
tion, perfusion, and viability state of the myocardium
Imaging protocol
Cardiac morphology is evaluated from axial and sagit-
tal two-dimensional (2D) image series covering the
entire heart using a navigator gated single-shot echo-
planar fast spin echo sequence (HASTE: Half-Fourier
Acquisition Single-shot Turbo spin-Echo) [31] (spatial
resolution = 1.9 × 1.3 mm2, slice thickness = 8 mm,
FOV = 340 mm, TR = 800 ms, TE = 26 ms, Matrix size =
256, flip angle = 160°, Partial Fourier = 5/8, Number of
echoes = 123, Time between echoes = 3 ms, and Band-
width = 698Hz/pixel).
Left ventricular function is evaluated using a time-
resolved (cine) 2D balanced Steady State Free Preces-
sion (TrueFISP: True Fast Imaging with Steady-state
Precession) [32, 33] sequence in which slice planes
were acquired yielding four-chamber, three-chamber,
and two-chamber views; short-axis views; and an
image of the left ventricular outflow tract (LVOT)
(spatial resolution = 1.8–2.4 × 1.2–1.6 mm2, slice thick-
ness = 8 mm, FOV = 300–400 mm, TR = 201–223 ms,
TE = 1.14–1.27 ms, Matrix size = 256, flip angle = 80°,
GRAPPA = 3, Bandwidth = 1149 Hz/pixel).
Rest and stress perfusion imaging are performed using
an ECG-triggered, contrast-enhanced, dynamic, 2D, gradi-
ent, echo, Fast Low Angle Shot (TurboFlash) [34] sequence
in three short axis slice planes (basis, mid, and apex)
(spatial resolution = 2.4 × 2.1 mm2, slice thickness = 10
mm, FOV= 330 mm, TR = 201 ms, TE = 1.05 ms, TI = 130
ms, Matrix size = 160, flip angle = 10°, Partial Fourier = 7/8,
GRAPPA= 2, and Bandwidth = 651Hz/pixel). (Fig. 3)
Stress perfusion imaging is carried out after an intra-
venous bolus injection of either 5 mL of Regadenoson
Fig. 2 Perfusion defect on myocardial perfusion scintigraphy. Myocardial perfusion scintigraphy with Tc-99 m Sestamibi: short-axis and horizontal
long-axis images during stress (upper rows) and rest (lower rows). A severe reversible perfusion defect is seen in the anteroseptal area of
the left ventricle
Fig. 3 Perfusion defect on coronary magnetic resonance imaging. Coronary magnetic resonance imaging during pharmacological stress induced
hyperemia (a) and at rest (b). The patient has an anteroseptal and lateral reversible perfusion defect in the midcardial segments of the left ventricle
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(Lexiscan, Astellas Pharma, USA) or following intraven-
ous adenosine-induced hyperemia. Adenosine is infused
for 6 min at 140 μg/kg/min. In case of an inadequate
peripheral haemodynamic response to standard dose (an
increase in heart rate of more than 10 beats per minute,
a systolic blood pressure drop of more than 10 mmHg
from baseline or no symptoms), the adenosine infusion
is increased to 170 μg/kg/min or even 210 μg/kg/min,
depending on the patient response. Independently of the
pharmacological stress approach (Regadenoson or adeno-
sine), an intravenous bolus of Gadovist® (Bayer Schering
Pharma AG, Germany) or Dotarem® (GD-DOTA, Guerbet
LCC, USA) with a concentration of 0.5–0.1 mmol/kg will
be administered at a flow rate of 4.0 mL/s through the left
cubital vein using a 18 G syringe followed by a 20 mL sa-
line flush (Medrad® Spectris Solaris® power injector, Bayer
Healthcare LCC, USA).
Rest perfusion scans are performed after pharmaco-
logical stress washout using the same sequence pa-
rameters and dose of contrast agent as for the stress
perfusion.
Viability evaluation of the myocardium is carried
out using a 2D single shot TrueFISP Phase Sensitive
Inversion Recovery (PSIR) [35] sequence in the short
axis plane of the heart (spatial resolution = 1.8 × 1.8 mm2,
slice thickness = 8 mm, FOV = 340 mm, TR = 700 ms,
TE = 1.09 ms, TI = 300 ms, Matrix size = 192, flip
angle = 40°, GRAPPA = 2, Bandwidth = 1447Hz/pixel).
The images are acquired approximately 10 min after con-
trast injection to insure optimal contrast enhancement.
CMRI analyses
CMRI analyses are carried out in an independent core
lab blinded for additional patient information and re-
sults. The image quality of all acquired images is scored
qualitatively using a scale from 1 to 3. Scores defined as
1 indicate a good image quality with no artifacts; scores
defined as 2 indicate a moderate image quality, which is
acceptable for clinical or research diagnosis; and scores
defined as 3 indicate poor image quality, and diagnosis is
impossible due to severe artifacts. Poor image quality
(score 3, non-diagnostic) is considered abnormal.
The images are also evaluated qualitatively with a bin-
ary outcome (normal/abnormal) based on the perfusion
analyses, presence of wall motion abnormalities, or low
ejection fraction. Perfusion analyses at stress and rest
are scored as significant, insignificant, or no defect based
on the 17-segment model of the American Heart Associ-
ation. Significant perfusion defects are defined as suben-
docardial or transmural signal changes in ≥ 2 contiguous
segments, corresponding to approximately 6–12 % of
the myocardium.
The presence of irreversible defects is considered ab-
normal if signal changes appear in ≥ 2 contiguous
segments on the viability scans. Evidence of regional wall
motion abnormalities is scored using a scale from 1 to 4:
1 is normal, 2 is hypokinetic, 3 is akinetic, and 4 is
dyskinetic.
A hybrid imaging analysis with combined information
from CCTA and CMRI blinded from the result of the
ICA are performed after the initial analysis.
Invasive coronary angiography-fractional flow reserve
(ICA-FFR) examination
Patient preparation
The ICA examination and the FFR assessments are per-
formed according to present clinical guidelines. The ICA
examinations are all conducted at Aarhus University
Hospital, Aarhus, Denmark, approximately 4 weeks
after referral to CCTA. The ICA is performed though
the radial or femoral artery route. Heparin 5000 IE is
administered when radial access is used, and 200 μg
of nitroglycerine is given intra-coronary after the first
angiographic projections.
Imaging protocol
All stenoses are visually assessed, and all stenoses above
30 % in vessels with a reference diameter above 2 mm
are examined, with at least two projections at least 30
degrees apart revolving around the axis of the vessels.
The overlap of vessels is avoided if possible. Angiog-
raphy is recorded at a time resolution of 15 frames per
second (fps).
FFR measurements are performed in all coronary seg-
ments with a diameter > 2 mm where ICA shows the
presence of stenosis with a diameter ≥ 30 % by visual
assessment. The position of the FFR wire is docu-
mented angiographically. FFR is measured using a pres-
sure wire (Aeris, St. Jude Medical, Minnetonka, MN,
USA) during continuous recording of the pressure
curves. Hyperaemia is induced by an intravenous ad-
enosine infusion of a 1 mg/mL concentration of adeno-
sine at 140 μg/L/min. The infusion rate is increased to
200 μg/L/min if a stable FFR value is not achieved.
Routine checks are made to ensure that ‘drift’ does not
occur after FFR recordings. If the drift value exceeds
1.04 or is below 0.96, the FFR-measurement is repeated.
Furthermore, all severe stenoses (> 90 %) in vessels
with a reference diameter above 2 mm where there is
no immediate indication of treatment, FFR is not pos-
sible or not attempted, are noted.
Imaging analysis
All evaluations are conducted with assessors blinded to
the patient’s CAD score, MPS, or CMRI examinations.
Hemodynamic significant obstructive CAD is defined
as FFR ≤ 0.80, or as high-grade stenosis (> 90 % diameter
stenosis) by visual assessment in a vessel ≥ 2.0 mm in
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diameter. If FFR is indicated in a vessel ≥ 2.0 mm but
not technically possible, then QCA-based stenosis will
be used with a cut-off of ≥ 50 % diameter reduction,
which defines an anatomically significant obstructive
CAD. The 2D QCA is performed in an independent core
lab (ClinFact, Leiden, The Netherlands) using QAngioXA
7.3 QCA software.
Follow-up
The cohort is followed for 10 years after the CCTA
examination. Data are extracted from the Civil Registra-
tion System (CRS) and National Patient Registry (NPR)
by obtaining diagnosis of CAD including acute coronary
syndrome, treatment with PCI/CABG, and causes of
death. Cases are verified through electronic medical re-
cords that include biochemistry and medication as well
as the results of diagnostic examinations.
Data collection and recordings
All study data are recorded in a secure web-based elec-
tronic case record form (eCRF) that enables logging of
all data entries (Biostata, Birkerød, Denmark). The CAD
score measurement, patient interview, and blood sam-
ples are obtained by trained study nurses.
All investigators have access to the eCRF. During
the study period, the monitoring of 100 % of the
proxy authorizations and informed consent forms and
20 % of the data for biochemistry, Agatston score, co-
morbidity, and adverse events is conducted by an ex-
ternal contract research organization (Klifo, Glostrup,
Denmark). The manuscript has been written following
the ‘Standard Protocol Items: Recommendations for
Interventional Trials’ and an additional file has been
added listing each paragraph and its location in the
manuscript (see Additional file 1).
Randomisation and blinding procedure
Patients are randomised using a randomisation module
in the eCRF. An external data manager is responsible for
the eCRF, including the randomisation module (Biostata,
Birkerød, Denmark). A random allocation sequence is
created using a standard computerized random-number
generator. The cardiologist analysing the CCTA rando-
mises patients when obstructive CAD is suspected on
CCTA. Randomisation is conducted without stratifica-
tion and in a 1:1 ratio to either MPS or CMRI. The ran-
domisation is open to all investigators and all patients.
The physicians performing ICA-FFR are blinded to the
results of the MPS or CMRI.
Data
The following data will be collected during the project
and registered in a dedicated eCRF:
 Demography—age, sex, and ethnical origin
 Co-morbidity
 Previous ischemic disease—stable angina pectoris,
stroke, and peripheral arterial disease
 Risk factors for ischemic heart disease—genetic
disposition, diabetes mellitus, hypertension and
hypercholesterolemia, blood pressure, heart rate,
weight, height, and smoking status
 Symptoms—typical, atypical, or unspecific chest
pain, New York Heart Association (NYHA)
functional class, and Canadian Cardiovascular
Society (CCS) score system of angina pectoris
 Echo—left ventricle ejection fraction (LVEF) and
significant valve disease
 CCTA—scan quality, Agatston calcium score,
anatomy, plaque type, and degree of stenosis and
radiation exposure
 CAD score—registration of the CAD score,
recording time, and positioning of the device
 MPS and CMRI—Scan quality, function, and
perfusion defects
 ICA-FFR—data concerning anatomy, localization of
stenosis, visual evaluation of stenosis, QCA
measurements, FFR measurements, and whether
treatment by PCI or CABG is performed
 Follow-up—cardiovascular events as well as possible
cardiovascular or other causes of death
 Adverse Events (AE)—all adverse events occurring
in the study period are registered
Endpoints and statistical analysis
Data analysis and reporting will follow the Standards for
Reporting of Diagnostic Accuracy (STARD) guidelines and
all demographic and baseline characteristics will be pre-
sented and analyzed using appropriate statistical methods.
First objective
The first objective of the study is to assess the diagnostic
accuracy of MPS and CMRI in two comparable samples
using hemodynamic significant obstructive CAD at ICA-
FFR as the reference standard. The diagnostic perform-
ance will be evaluated on a patient level by sensitivity,
specificity, predictive values, and likelihood ratios as well
as by a binary abnormal/normal test outcome. The sen-
sitivity and specificity of the MPS and CMRI are being
compared by Chi2 test.
Second objective
The secondary objective is to evaluate the diagnostic
precision of the CAD score using anatomical significant
obstructive CAD at CCTA and ICA-QCA as the ref-
erence standard. The diagnostic performance will be
evaluated on a patient level as the area under curve
receiver operating characteristics (ROC-AUC) with
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the CAD score as a continuous variable. The CAD
score is dichotomized with a positive value above 20,
25, and 30, respectively, and performance is reported
with sensitivity, specificity, positive predicative value,
negative predicative value, and diagnostic accuracy. In
risk stratification the CADScor system operates with
three intervals in CAD: < 20, 20–30, and >30 for low,
intermediate and high risk, respectively.
Secondarily, the same calculations are made using
hemodynamic significant obstructive CAD with ICA-
FFR as the reference standard. Comparisons between
subgroups are evaluated with ROC-AUC regression
analysis. A comparison of the CAD score and MPS or
CMRI is evaluated with the McNemars test of sensi-
tivity and specificity at a CAD-score cut-off of 20, 25,
and 30.
For all statistical analyses, a two-tailed p value < 0.05
was considered statistically significant, and 95 % confi-
dence intervals are being reported when appropriate.
Statistical analysis is performed using dedicated statis-
tical software (STATA 13, StataCorp, College Station,
TX, USA)
Sample size
On the basis of previous data, we assumed a sensitivity
and specificity of 0.83 for diagnosing obstructive CAD
for both MPS and CMRI in patients referred to further
examinations after CCTA [15, 17, 22, 36]. Based on
these assumptions, a final randomised study cohort of
300 patients is required for a minimum of 10 % absolute
precision on both sides (half width of the 95 % confi-
dence interval (CI)) of the expected sensitivity and speci-
ficity for both MPS and CMRI. A minimum of 300
patients are needed to achieve sufficient power in the
randomised study. To establish this study cohort, we es-
timate that a primary cohort of approximately 2,000 pa-
tients referred to CCTA is needed based on the
assumption that 15–20 % of patients need further testing
after CCTA.
Ethical considerations
The study follows the principles outlined in the Dec-
laration of Helsinki. The Danish Data Protection
Agency (Case no. 1-16-02-345-14), Danish Health and
Medical Authority (Case no. 20140 71252), and the
regional committee of Central Denmark engaged in
health research ethics (Case no. 1-10-72-190-14) have
approved the study protocol. Patients participate in
the study only after providing informed written con-
sent both for the randomised part of the study and
for their blood samples to be stored in a biobank.
The study was registered at ClinicalTrials.gov (Identi-
fier: NCT01344434).
Discussion
The use of CCTA has proven to be a valid tool for ruling
out CAD [6–9] in patients with a low to intermediate
pre-test likelihood of CAD. However, the low positive
predictive value of CCTA causes ‘unnecessary’ down-
stream ICA examinations in the sense that no revascu-
larization is required. The need for more specific
strategies for non-invasive diagnostic work-up of pa-
tients with suspected CAD was demonstrated in a large
study comprising 398,978 patients where elective cardiac
catheterization showed obstructive CAD in only 38 % of
these patients [37]. The Dan-NICAD study aim to test
the idea that more patients could potentially avoid un-
necessary ICAs by performing a secondary perfusion-
imaging test in patients where obstructive CAD could
not be excluded with the CCTA. In prior studies looking
at low to intermediate pre-test populations, approxi-
mately 70 % of the patients did not have obstructive
CAD on CCTA [11]. Patients in the Dan-NICAD study
in whom obstructive CAD is not excluded by CCTA will
be randomised 1:1 to either MPS or CMRI with ICA-
FFR as a reference standard for a head-to-head compari-
son of the diagnostic accuracy of these two modalities.
Several other studies have tested the accuracy of these
two techniques. In the CE-MARC study [15], 752 pa-
tients with intermediate to high pre-test risks of ob-
structive CAD underwent both MPS and CMRI with
ICA-QCA as a reference standard. The study showed
both higher sensitivity and specificity of CMRI com-
pared to MPS. The MR-IMPACT study [38] also made a
head-to-head comparison of the two techniques and
showed superiority of CMRI. Here, the patients were
highly selected. Patients had either undergone an ICA
(positive or negative) or had a positive MPS and were
scheduled for ICA. Both studies used ICA-QCA, a refer-
ence standard proven not to be ideal [3], as it compares
functional tests with an anatomical test. ICA-QCA is
shown to overestimate the severity of CAD compared to
FFR [3]. The MARCC study [11], with a population of
low-to intermediate pre-test probability, tested the com-
bined use of CCTA and CMRI for the diagnostic evalu-
ation of patients with suspected CAD using ICA-FFR as
a reference standard when disease was suspected on
either CCTA or CMRI. The study showed improved spe-
cificity and diagnostic accuracy using a combined set-up.
As the availability of CMRI is limited in most clinical
settings, we chose a stepwise approach with CCTA as
the initial examination based on the high negative pre-
dictive value of this approach. [11]. The CAD score
combined with the Diamond-Forrester score compared
to Diamond-Forrester score alone has previously been
shown to improve the risk assessment in patients sus-
pected of stable CAD [29]. Optimizing the risk assess-
ment might reduce the use of more advanced diagnostic
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testing and can potentially serve as an easy, safe, and
low-cost supplement in diagnosing CAD.
Perspective
Despite the advances in knowledge and research within
the field of CAD large variations still exist in the diag-
nostic approach for this large group of patients. The ef-
fect of a secondary perfusion imaging examination after
CCTA in a group of patients with low to intermediate
pre-test probability of CAD could potentially reduce the
number of unnecessary ICAs where no revascularisation
is required. The results of this study are expected to
make an important contribution to the improvement of
diagnostic strategies for patients suspected of CAD.
Trial status
The trial is ongoing. The first patient was enrolled on
11 September 2014. As of September 2015, 1,100 sub-
jects have been enrolled, and 226 subjects (23.5 %)
have been randomised. Enrolment completion is ex-
pected in May 2016.
Additional file
Additional file 1: SPIRIT checklist. Each SPIRIT checklist paragraph has
been addressed regarding location in the manuscript. In cases where the
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not applicable. (PDF 117 kb)
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